Table 2

Patient characteristics

AdalimumabPlaceboAll patients
Treatment groupN=34N=36N=70
Sex (female)24 (70.6%)28 (77.8%)52 (74.3%)
Age (years)74.5 (69–78)74.5 (67–80.5)74 (68–80)
Weight (kg)70 (60–74)64.75 (58–76.7)67 (58–74)
Size (cm)164.4 (159–172)161 (155–168)162 (156–170)
Body mass index (kg/m²)23.7 (21.6–27.8)25.9 (22.1–29.2)24.9 (22.0–28.1)
Hypertension17 (50.0%)23 (63.9%)40 (57.1%)
Osteoporosis2 (5.9%)6 (16.7%)8 (11.4%)
Chronic bronchitis1 (2.9%)2 (5.6%)3 (4.3%)
Mild cardiac insufficiency1 (2.9%)1 (2.8%)2 (2.9%)
Symptoms and signs
Fever10 (29.4%)8 (22.2%)18 (25.7%)
Weight loss15 (44.1%)21 (58.3%)36 (51.4%)
Recent-onset headaches22 (64.7%)30 (83.3%)52 (74.3%)
Temporal artery abnormalities21 (61.8%)19 (52.8%)40 (57.1%)
Scalp tenderness14 (41.2%)15 (41.7%)29 (41.4%)
Jaw claudication5 (14.71%)9 (25.0%)14 (20.0%)
Non-ocular ischaemic manifestations1 (2.9%)1 (2.8%)2 (2.9%)
Peripheral arthritis2 (5.9%)4 (11.1%)6 (8.6%)
Polymyalgia rheumatica-like symptoms14 (41.2%)20 (55.6%)34 (48.6%)
Positive temporal artery biopsy22 (64.7%)28 (77.8%)50 (71.4%)
Biological tests
Haemoglobin level (g/dl)11.6 (10.3–12.7)11.4 (10.7–12.4)11.4 (10.7–12.7)
Platelet count (×103/mm3)394.0 (337.0–467.0)417.5 (375.0–539.0)402.0 (363.0–503.0)
Creatinine level (µmol/L)83.4 (65.0–96.9)79.6 (64.6–88.5)81.0 (65.0–89.0)
Erythrocyte sedimentation rate58.0 (46.0–90.0)57.0 (41.0–100.0)57.5 (45.0–100.0)
C-reactive protein55.0 (17.9–80)37.2 (16.0–87.0)43.6 (16.0–85.0)